The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...

AstraZeneca and its development ... with a history of asthma exacerbations and uncontrolled asthma receiving currently approved inhaled treatment versus placebo. The trial showed annual asthma ...

The move comes in the wake of a letter sent by Congressional leaders in January advising AstraZeneca that they were launching ...

Airsupra (PT027), a new asthma rescue treatment developed by AstraZeneca (AZ) and development partner Avillion, has been approved by the US Food and Drug Administration (FDA). A first-in-class ...

Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart to treat patients with severe asthma, the IL-5 ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...

AstraZeneca BioPharmaceuticals Business Unit executive vice-president Ruud Dobber stated: “The approval is an important step forward in the treatment of severe asthma in China, which affects mil ...

AstraZeneca’s Fasenra (benralizumab ... It initially presents as adult-onset asthma before progressing to multi-organ failure ...

On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers ...

[1] All of these pathophysiologic features are largely represented in asthma, and therefore, anticholinergic drugs have been ... and research activities from: AstraZeneca, Boehringer Ingelheim ...

Weather conditions in the United Arab Emirates (UAE) trigger asthma. While most adults are given medication to deal with such ailments, children often need emergency nebulisation treatments that are ...

AstraZeneca is capping out-of-pocket costs ... said it welcomes efforts to make asthma drugs more affordable and called on ...